Jeffrey Graham, MD, Talks Immunotherapy Use in Frontline Non-Clear Cell RCC

March 23, 2021
Jeffrey Graham, MD, FRCPC

CancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, to discuss the effectiveness of immune checkpoint inhibitors as frontline therapy for non–clear cell renal cell carcinoma

CancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, assistant professor in the Department of Internal Medicine, Section of Haematology/Oncology at the University of Manitoba in Winnipeg, Canada, to discuss an abstract regarding the effectiveness of immune checkpoint inhibitors (ICIs) as frontline therapy for non–clear cell renal cell carcinoma (nccRCC) presented at the recent Genitourinary Cancers Symposium.

“The goal of our study was to evaluate the effectiveness of first-line immune checkpoint inhibitor–based therapy in advance non–clear cell renal cell carcinoma, and to accomplish this, we performed a retrospective analysis of a large international database, the IMDC,” Graham said. “We divided patients into 3 groups based on the type of first-line therapy they received and essentially stratified them.”

Patients were categorized by the receipt of ICIs or targeted VEGF or mTOR inhibitors to assess response rates, time to treatment failure, or overall survival by a multivariable cox regression model to assess outcomes in the real-world setting.

Results showed that treatment with ICIs appear the be associated with improved OS over other available treatment options for nccRCC, with results requiring confirmation in prospective randomized clinical trials.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Brightcove: 6242779710001

Reference:

Graham J, Wells C, Dudani S, et al. Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021; 39(suppl6):316. doi: 10.1200/JCO.2021.39.6_suppl.316